Does RAD 140 increase libido? Both answers exist, and neither comes from a trial. Beyond the trial data, Testolone is described as raising sex drive most often in the first weeks, and then as lowering it, sometimes with weaker erections, while other accounts describe no change at all.
The only measurement comes from a published case report, and what it measured was the hormonal change that the accounts blame for a fall in desire: in one man, supplements containing RAD140 coincided with suppression of endogenous testosterone, the principal androgen the testes secrete. Once the supplements were discontinued that testosterone suppression resolved and hormone production came back to normal, but the products also held hormones their labels never mentioned, so RAD140 alone cannot be blamed.
Why would a compound built for muscle and bone reach libido at all? Because of where it acts. RAD140 is a nonsteroidal selective androgen receptor modulator, potent and orally bioavailable, and it works tissue-selectively at the androgen receptor, the protein inside cells that responds to the androgens; desire is one of the functions those hormones govern. Researchers first characterised that selectivity in rat and monkey models of anabolic androgen action; it is the RAD 140 mechanism of action. The wider RAD 140 side effects, beyond the sexual ones, belong to the parent article.
This article therefore does three things. It reads the case report and the animal studies for what they measured, it sets out what is described outside the trials about libido, erections and recovery, and it leaves aside testicular volume and pain, fertility, and liver and cardiac outcomes, which have their own pages.
Hormone suppression in a published case report
The patient in the case report was a 40-year-old man who had been exposed for six months to commercially sold supplements. He presented with bilateral gynaecomastia, growth of male breast tissue on both sides, and biochemical hypogonadotropic hypogonadism, which is low serum testosterone arising from weak pituitary signalling to the testes. One of those pituitary signals is luteinising hormone (LH), the hormone that drives testosterone production in the testes, and it is the signal that compounds of this class bear on.
The supplements held RAD-140 together with two further compounds, the PPAR-delta agonist cardarine and the growth hormone secretagogue MK-677, which raises the secretion of growth hormone, the pituitary hormone of growth and metabolism. Analysis of all three supplements also detected hormones that none of the labels declared. With that much in the mix, the suppression cannot be attributed to RAD140 alone.
The record is a hormonal and breast-tissue record, because libido and erectile function lay outside what the clinicians observed. What the case shows, in one patient, is the kind of suppression that descriptions outside the trials link with a fall in libido; sexual function itself it never measured.
Is there any human trial data on RAD140 and sexual function?
This report describes the discovery of RAD140, a potent, orally bioavailable, nonsteroidal selective androgen receptor modulator (SARM). The characterization of RAD140 in several preclinical models of anabolic androgen action is also described.
The answer is no. Libido and erectile function have never been measured in anyone receiving RAD140 in a clinical study. The one source of human trial data is the early-phase RAD140 clinical trial in postmenopausal women with advanced hormone receptor-positive breast cancer, a safety study that used the compound’s trial name vosilasarm; its record covers raised liver enzymes and gastrointestinal effects, with sexual function nowhere among the endpoints. What is said about RAD140 and sexual desire therefore rests on animal studies and on inference from androgen suppression, not on anything measured in men.
Does RAD140 raise or lower libido overall, and how often does each happen?
Among the effects described outside the trials, a change in libido under RAD140 runs in both directions, and a rise is described about as often as a fall. The accounts take these forms:
a marked rise in sex drive, the desire side of sexual function, widely described as frequent arousal, firmer and more frequent erections, and more morning erections, the spontaneous erections present on waking, and in a few of those accounts running contrary to what earlier descriptions had predicted
no change at all, in a third set of accounts
a rise that later fades, described more often than a rise that holds through the whole exposure
a fall, described as desire draining away, with softer erections and diminished interest in a partner
across all of them, other compounds often described alongside RAD140 in accounts outside the published studies, so descriptions of RAD 140 libido change rarely rest on one compound alone
In those accounts nothing is measured and no course is followed over time, so how often each direction occurs cannot be counted. Both directions appear often, there and in the wider accounts of RAD-140 on Reddit and YouTube.
Why does libido spike in the first weeks and then crash by week 5?
A libido spike in the first weeks is described, outside the published trials, as giving way to a fall soon afterwards, and the pattern is put down to two effects arriving at different speeds: the androgen action of the compound comes first, and the fall in endogenous testosterone follows later. The timing across those descriptions is fairly consistent. The rise sits in the first days or weeks, and the fall follows a few weeks on, sometimes abruptly rather than by degrees. Beyond the trial data, several explanations are offered for that second phase:
suppression, the commonest of them, the shutdown of endogenous hormone production signalled through the pituitary
low oestradiol concentrations, described as brought by that suppression, oestradiol being the principal oestrogen in circulation
in one account, raised prolactin, also put down to that suppression, a pituitary hormone whose excess dampens sexual desire
other compounds present in the same weeks as RAD 140, so the timing is hard to attribute to any single agent
occasionally, the early rise put down to confidence rather than to androgen action
Those accounts measure none of the hormones behind the timing. The lag between rise and fall is at least consistent with suppression as its cause, since suppression of the hormonal axis builds over weeks rather than days.
How common is a major loss of libido on RAD140?
Outside the published trials, a major loss of sex drive under RAD140 is described as a minority outcome, yet one that recurs across many separate accounts. The loss takes these forms in those accounts:
desire gone altogether
erections absent
sometimes, onset within days of first exposure
sometimes, onset late in exposure
in a few descriptions, a loss that persisted after exposure had ended
In those accounts a loss of that severity is a less common but recognised outcome, and it follows suppression of endogenous testosterone rather than any direct action on genital tissue. Its frequency has not been established, because the material holds no count of cases.
Why do some users get no libido boost at all?
Outside the published trials, some individuals exposed to RAD140 are described as showing no libido boost at all, and the first explanation offered is variation between individuals. Androgen receptor sensitivity and the depth of testosterone suppression differ from one person to the next, so the same exposure need not move desire in the same direction. Beyond the trial data, a libido already high before exposure is described as leaving little room for any noticeable rise.
In those accounts two further explanations appear. Other compounds present at the same time, in the combinations known as RAD140 stacks, are described as able to mask or offset whatever RAD140 does alone, and the products themselves are open to doubt, because unapproved products of this kind are widely held to be mislabelled or to contain less than they declare. A last explanation, offered in descriptions beyond the trials, is that the rise described elsewhere reflects expectation rather than androgen action.
Can RAD140 cause erectile dysfunction or loss of morning erections?
Beyond the trial data, RAD140 is described as linked with erection problems that run from weaker rigidity and the loss of morning erections, the spontaneous ones present on waking, to the inability to attain or keep an erection sufficient for intercourse, known as erectile dysfunction. Other accounts describe the opposite, firmer than usual. Onset is placed within the first days or weeks in some accounts and late in exposure in others, and in descriptions beyond the trials desire sometimes stayed intact while rigidity failed during intercourse and morning erections disappeared a few weeks in.
The same accounts also describe erection problems that began only once exposure had ended, or during the medicines given afterwards. Many of them involve several compounds administered together, so any attribution to a single compound stays loose.
To the question does RAD 140 cause erectile dysfunction, the answer generally given outside the trials is an indirect mechanism. It begins with suppression of the hypothalamic-pituitary-gonadal axis, the hormonal chain from hypothalamus through pituitary to the testes, which lowers luteinising hormone and endogenous testosterone. Penile tissue and the central arousal pathways are then described as short of the hormones they need, because the compound is not converted to oestradiol or to dihydrotestosterone.
Within that mechanism, spontaneous nocturnal erections are widely regarded as among the most testosterone-sensitive signs of erectile function, so their loss is treated as an early marker of androgen suppression. That loss is generally thought to ease as the axis recovers once exposure ends, although its persistence beyond that point is described as a risk rather than as a measured outcome.
Does RAD140 affect ejaculation and orgasm?
Neither ejaculation nor orgasm is generally held to be a direct target of RAD140, and none of the studies this article draws on measured either. Where changes are described, they are put down to the suppression of endogenous testosterone, which runs through lowered luteinising hormone and follicle-stimulating hormone. Accounts outside the published studies describe the first three of the following changes, and low testosterone of that kind is widely understood to accompany all four:
ejaculate, the fluid emitted at orgasm, thinner
orgasm weaker
orgasm delayed
sperm production reduced
In those accounts the link is inferred from the hormones, never measured directly.
Does the dose change the effect on libido?
Outside the trial record, the dose is described as shifting the effect on libido only loosely. A fall in desire appears at low doses and at high ones alike, though several accounts link the higher doses with stronger effects, and the exceptions run both ways: a fall within days where the dose was low, and thinner ejaculate with a heavier loss of desire where the dose sat well above those described elsewhere. In one isolated account outside the published trials, a very high dose is described as having raised testosterone, a change in the opposite direction.
The descriptions attributed to RAD140 doses are the hardest of all to read, since most of the accounts behind them involved other compounds as well. Suppression of the body’s own testosterone is generally held to deepen as the dose rises, and effects on desire are described as stronger at the higher end. The relation is not strict, however, since marked suppression is also described at low doses.
Hormone recovery in the case report after the supplements stopped
Once the supplements were discontinued the patient’s symptoms resolved fully: the bilateral gynaecomastia settled and the hypogonadotropic hypogonadism normalised, with the measured values back inside their reference ranges. A suppression that reversed once the supplements stopped is the strongest statement this evidence supports in humans, and it rests on a single patient whose products also held undeclared hormones. The published record gives no interval to normalisation, so no recovery window can be read from the case.
The case patient before and after stopping
Finding
While taking the supplements
After stopping
Breast tissue
Bilateral gynaecomastia
Resolved
Reproductive hormones
Biochemical hypogonadotropic hypogonadism
Normalised
Overall symptoms
Present after 6 months of use
Full resolution
Libido and erections
Not recorded
Not recorded
Time to recovery
Not applicable
Not reported
How long does low libido last after a RAD140 cycle and PCT?
Low libido after exposure to RAD140 ends is generally held to last from a few weeks to several months, lifting as the hypothalamic-pituitary-gonadal axis recovers. The axis is held to recover more slowly after longer or heavier exposure, and the medicines given once exposure ends have not been shown to guarantee a faster return.
Outside the published trials, low libido is described as running much the same course: desire returned within weeks in some accounts and stayed low for many months in others, and in a few it fell only after exposure had ended. Beyond the trial data, some of those courses are described as followed by medicines meant to restart endogenous hormone production, which the accounts call post-cycle therapy, or RAD 140 PCT.
In those accounts, where desire stays low for months, the usual next step in the medical literature is RAD 140 blood work: serum testosterone, luteinising hormone, follicle-stimulating hormone, oestradiol and prolactin, a pituitary hormone whose excess dampens sexual desire. Those measurements let persistent secondary hypogonadism, or another cause, be sought rather than assumed.
Does libido always come back after stopping, or can the loss be lasting?
In descriptions beyond the trials, libido returns in most cases once exposure ends, though in a few the recovery is described as incomplete and the loss as possibly permanent. Incomplete recovery of erectile function has also been described as a rare outcome, usually where several compounds were present at once, while desire has elsewhere been described as returning more strongly than before.
In those accounts a return of libido is the usual outcome, because desire tracks the testosterone produced by the testes and that production is widely understood to recover over the following months. Delayed or incomplete recovery is recognised after high-dose or prolonged exposure and after combinations of several androgenic compounds.
Does PCT actually bring libido and erections back?
Outside the trials, PCT brings desire and erections back in some accounts and fails to bring them back in others. The medicines in those accounts include enclomiphene, a selective oestrogen receptor modulator (SERM) that raises luteinising hormone, and human chorionic gonadotrophin (hCG), a hormone that stimulates the testes directly. The outcomes described after PCT are these:
sexual attraction and erections rebounding within days of the first administration of enclomiphene, in accounts outside the published studies
hCG described in one account as maintaining testicular hormone production
erections lost or worsened during the recovery phase itself, in descriptions beyond the trials
the effects of these medicines’ own on oestrogen and mood, which can dampen desire for a time
persistent erectile dysfunction, which is understood in the clinical literature to warrant assessment of the hypothalamic-pituitary-gonadal axis rather than attribution to the recovery phase alone
In those accounts SERMs raise luteinising hormone and testosterone where testicular production has been suppressed, and sexual function follows that recovery, though the timing of the recovery varies.
What RAD140 supplements were found to contain
All three supplements in the case report turned out to hold testosterone, oestradiol and growth hormone, none of them named on the labels, and by liquid chromatography mass spectrometry, which separates compounds and identifies them by mass, it found an unidentified compound co-eluting close to the testosterone peak. The Australian medicines regulator, the Therapeutic Goods Administration (TGA), found the opposite fault in its own testing: unapproved SARM products were significantly under-dosed, that is, they supplied less of the declared compound than the label stated. Undeclared hormones on one side and under-dosing on the other bracket the problem of RAD140 quality.
[Figure 1. Undeclared hormones in three supplements. In one published case, three gym supplements taken for six months held the SARM, MK-677 and cardarine as declared. Analysis also detected testosterone, oestradiol and growth hormone in all three, plus one unidentified compound.]
For libido that means an effect described outside the trials may come from a hormone that nobody declared, or may not come from RAD140 at all where too little of the compound was present to act.
Laboratory work is in a different position, because the contents of a vial can be known before an experiment begins. The RAD-140 for sale in our shop comes with batch and purity data for each lot, and the same documentation covers the rest of our UK SARMs range.
What the animal studies show about RAD140 and the brain
The animal studies on RAD140 and the brain show that the compound reaches the brain and produces androgen action there. RAD140 matched testosterone in reducing cell death from apoptotic insults in cultured rat hippocampal neurons, and the authors traced that neuroprotection to MAPK signalling through the mitogen-activated protein kinase cascade, because an inhibitor of that cascade abolished it.
The whole-animal work used adult male rats that had been gonadectomised, surgically deprived of their gonads. In them the SARM RAD140 produced androgen action in peripheral tissues while largely sparing the prostate, switched on androgenic gene regulation in the brain and reduced the loss of hippocampal neurons after an excitotoxic kainate lesion. An earlier characterisation across rat and monkey models had already described the compound as potent and orally bioavailable.
These data supply the biological ground that any claim about desire would need, since such a claim begins with androgen action in the brain. They measured neuronal survival, gene regulation and the response of peripheral tissues, not sexual behaviour or erectile function.
RAD140 in the animal studies
Experiment
Model
Finding
Sexual behaviour measured
Apoptotic insult
Cultured rat hippocampal neurons
Cell death reduced as effectively as with testosterone; dependent on MAPK signalling
No
Peripheral and prostate tissue
Gonadectomised adult male rats
Tissue-specific androgen action that largely spared prostate
No
Brain gene regulation
Gonadectomised adult male rats
Androgenic gene regulation activated
No
Kainate lesion
Gonadectomised adult male rats
Loss of hippocampal neurons reduced
No
First characterisation
Rat and monkey models
Potent and orally bioavailable
No
Limits of the evidence on RAD140 and sex drive
The human evidence assembled here amounts to one case report, whose products held hormones their labels did not name and whose record describes hormonal and breast-tissue findings rather than libido. The animal studies measured neuronal and peripheral-tissue outcomes, so they cannot be read as data on sexual function. Everything else comes from descriptions outside the trials, which measurement does not confirm and which often involve several compounds at once and products of unknown content. Those limits cut both ways: such material can neither confirm nor rule out a rise in desire or its loss. No trial among this article’s sources measured libido, erectile function or recovery under the compound.
What each source measured on RAD140
Source
Design
Subjects
What it measured
Sexual function measured
Chong et al. 2024
Case report with product analysis
One 40-year-old man, 6 months of supplements
Breast tissue, reproductive hormones, product contents
No
Jayaraman et al. 2014
Cell culture and rat lesion model
Rat hippocampal neurons; gonadectomised adult male rats
Neuron survival, androgenic gene regulation in the brain, peripheral tissue and prostate response
Outside the published trials RAD140 is linked with reduced rigidity, the absence of any erection and lost morning erections, and in other accounts with greater rigidity than usual. The mechanism generally held to apply is indirect, through suppression of endogenous testosterone rather than any direct action on penile tissue, and no controlled study has measured erectile function under the compound.
How long does low libido last after a cycle?
From a few weeks to several months, as a rule. Outside the published trials the course is described the same way, desire returning within weeks in some accounts and staying low months later in others, and where it persists, hormonal blood testing is the usual next step in clinical practice.
In which week does the libido drop usually start?
Outside the trial record, the fall is placed a few weeks into exposure, after a rise in the first days or weeks. A minority of accounts put it within the first days, others only after exposure had ended, so no single week is typical.
On the question of whether RAD 140 increases libido, the early rise in sex drive and its later fall, erectile dysfunction, the loss of morning erections and low libido lasting after exposure has ended are known only from descriptions outside the trials. No published study among this article’s sources has measured them.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
What did laboratory analysis find in the supplements of the published case report?
Only RAD140, at the exact strength printed on the labels
Testosterone, oestradiol and growth hormone, all undeclared ✓
Cardarine and MK-677, with no trace of RAD140 present
Prolactin and luteinising hormone, neither named on the labels
Besides RAD-140, MK-677 and cardarine, all three products held testosterone, oestradiol and growth hormone that no label named, so the man's suppression cannot be pinned on RAD140 alone.
What happened to the case patient's hormones and breast tissue once the supplements were stopped?
They stayed suppressed for several years afterwards
They recovered only after hormone medicines were given
They normalised, and the gynaecomastia fully resolved ✓
They normalised, but the gynaecomastia remained in place
Stopping the supplements led to full resolution of his symptoms, including normal reproductive hormones, though the report recorded neither libido nor erections and gave no time to recovery.
What did the rat studies show about RAD140 and the brain?
It increased mating behaviour in the gonadectomised male rats
It switched on androgen gene regulation and spared neurons ✓
It acted on the prostate as strongly as testosterone did
It stayed outside the brain and acted only in muscle
RAD140 activated androgenic gene regulation in the rat brain and reduced neuron loss after kainate while largely sparing prostate, but sexual behaviour was never measured.
What did Australia's medicines regulator find when it tested unapproved SARM products?
They held far more of the compound than the labels stated
They matched their labels closely in nearly all samples
They held much less compound than their labels stated ✓
They were mostly testosterone under a SARM label
The TGA found unapproved SARM products contained significantly less of the declared compound than their labels claimed, so a described effect may not come from RAD140 at all.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Postdoctoral Clinical Research Fellow; Specialty Registrar in Endocrinology and Diabetes
Bonnie Grant is a postdoctoral clinical research fellow and a specialty registrar in endocrinology and diabetes in the Department of Metabolism, Digestion and Reproduction at Imperial College London. Bonnie specialises in reproductive medicine and fertility.
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
Does RAD 140 increase libido? Erections and the evidence
By Elizabeth Hyams · Reviewed by Bonnie Grant, MBBS
Published · Updated · 19 min read
Does RAD 140 increase libido or lower it?
Does RAD 140 increase libido? Both answers exist, and neither comes from a trial. Beyond the trial data, Testolone is described as raising sex drive most often in the first weeks, and then as lowering it, sometimes with weaker erections, while other accounts describe no change at all.
The only measurement comes from a published case report, and what it measured was the hormonal change that the accounts blame for a fall in desire: in one man, supplements containing RAD140 coincided with suppression of endogenous testosterone, the principal androgen the testes secrete. Once the supplements were discontinued that testosterone suppression resolved and hormone production came back to normal, but the products also held hormones their labels never mentioned, so RAD140 alone cannot be blamed.
Why would a compound built for muscle and bone reach libido at all? Because of where it acts. RAD140 is a nonsteroidal selective androgen receptor modulator, potent and orally bioavailable, and it works tissue-selectively at the androgen receptor, the protein inside cells that responds to the androgens; desire is one of the functions those hormones govern. Researchers first characterised that selectivity in rat and monkey models of anabolic androgen action; it is the RAD 140 mechanism of action. The wider RAD 140 side effects, beyond the sexual ones, belong to the parent article.
This article therefore does three things. It reads the case report and the animal studies for what they measured, it sets out what is described outside the trials about libido, erections and recovery, and it leaves aside testicular volume and pain, fertility, and liver and cardiac outcomes, which have their own pages.
Hormone suppression in a published case report
The patient in the case report was a 40-year-old man who had been exposed for six months to commercially sold supplements. He presented with bilateral gynaecomastia, growth of male breast tissue on both sides, and biochemical hypogonadotropic hypogonadism, which is low serum testosterone arising from weak pituitary signalling to the testes. One of those pituitary signals is luteinising hormone (LH), the hormone that drives testosterone production in the testes, and it is the signal that compounds of this class bear on.
The supplements held RAD-140 together with two further compounds, the PPAR-delta agonist cardarine and the growth hormone secretagogue MK-677, which raises the secretion of growth hormone, the pituitary hormone of growth and metabolism. Analysis of all three supplements also detected hormones that none of the labels declared. With that much in the mix, the suppression cannot be attributed to RAD140 alone.
The record is a hormonal and breast-tissue record, because libido and erectile function lay outside what the clinicians observed. What the case shows, in one patient, is the kind of suppression that descriptions outside the trials link with a fall in libido; sexual function itself it never measured.
Is there any human trial data on RAD140 and sexual function?
The answer is no. Libido and erectile function have never been measured in anyone receiving RAD140 in a clinical study. The one source of human trial data is the early-phase RAD140 clinical trial in postmenopausal women with advanced hormone receptor-positive breast cancer, a safety study that used the compound’s trial name vosilasarm; its record covers raised liver enzymes and gastrointestinal effects, with sexual function nowhere among the endpoints. What is said about RAD140 and sexual desire therefore rests on animal studies and on inference from androgen suppression, not on anything measured in men.
Does RAD140 raise or lower libido overall, and how often does each happen?
Among the effects described outside the trials, a change in libido under RAD140 runs in both directions, and a rise is described about as often as a fall. The accounts take these forms:
In those accounts nothing is measured and no course is followed over time, so how often each direction occurs cannot be counted. Both directions appear often, there and in the wider accounts of RAD-140 on Reddit and YouTube.
Why does libido spike in the first weeks and then crash by week 5?
A libido spike in the first weeks is described, outside the published trials, as giving way to a fall soon afterwards, and the pattern is put down to two effects arriving at different speeds: the androgen action of the compound comes first, and the fall in endogenous testosterone follows later. The timing across those descriptions is fairly consistent. The rise sits in the first days or weeks, and the fall follows a few weeks on, sometimes abruptly rather than by degrees. Beyond the trial data, several explanations are offered for that second phase:
Those accounts measure none of the hormones behind the timing. The lag between rise and fall is at least consistent with suppression as its cause, since suppression of the hormonal axis builds over weeks rather than days.
How common is a major loss of libido on RAD140?
Outside the published trials, a major loss of sex drive under RAD140 is described as a minority outcome, yet one that recurs across many separate accounts. The loss takes these forms in those accounts:
In those accounts a loss of that severity is a less common but recognised outcome, and it follows suppression of endogenous testosterone rather than any direct action on genital tissue. Its frequency has not been established, because the material holds no count of cases.
Why do some users get no libido boost at all?
Outside the published trials, some individuals exposed to RAD140 are described as showing no libido boost at all, and the first explanation offered is variation between individuals. Androgen receptor sensitivity and the depth of testosterone suppression differ from one person to the next, so the same exposure need not move desire in the same direction. Beyond the trial data, a libido already high before exposure is described as leaving little room for any noticeable rise.
In those accounts two further explanations appear. Other compounds present at the same time, in the combinations known as RAD140 stacks, are described as able to mask or offset whatever RAD140 does alone, and the products themselves are open to doubt, because unapproved products of this kind are widely held to be mislabelled or to contain less than they declare. A last explanation, offered in descriptions beyond the trials, is that the rise described elsewhere reflects expectation rather than androgen action.
Can RAD140 cause erectile dysfunction or loss of morning erections?
Beyond the trial data, RAD140 is described as linked with erection problems that run from weaker rigidity and the loss of morning erections, the spontaneous ones present on waking, to the inability to attain or keep an erection sufficient for intercourse, known as erectile dysfunction. Other accounts describe the opposite, firmer than usual. Onset is placed within the first days or weeks in some accounts and late in exposure in others, and in descriptions beyond the trials desire sometimes stayed intact while rigidity failed during intercourse and morning erections disappeared a few weeks in.
The same accounts also describe erection problems that began only once exposure had ended, or during the medicines given afterwards. Many of them involve several compounds administered together, so any attribution to a single compound stays loose.
To the question does RAD 140 cause erectile dysfunction, the answer generally given outside the trials is an indirect mechanism. It begins with suppression of the hypothalamic-pituitary-gonadal axis, the hormonal chain from hypothalamus through pituitary to the testes, which lowers luteinising hormone and endogenous testosterone. Penile tissue and the central arousal pathways are then described as short of the hormones they need, because the compound is not converted to oestradiol or to dihydrotestosterone.
Within that mechanism, spontaneous nocturnal erections are widely regarded as among the most testosterone-sensitive signs of erectile function, so their loss is treated as an early marker of androgen suppression. That loss is generally thought to ease as the axis recovers once exposure ends, although its persistence beyond that point is described as a risk rather than as a measured outcome.
Does RAD140 affect ejaculation and orgasm?
Neither ejaculation nor orgasm is generally held to be a direct target of RAD140, and none of the studies this article draws on measured either. Where changes are described, they are put down to the suppression of endogenous testosterone, which runs through lowered luteinising hormone and follicle-stimulating hormone. Accounts outside the published studies describe the first three of the following changes, and low testosterone of that kind is widely understood to accompany all four:
In those accounts the link is inferred from the hormones, never measured directly.
Does the dose change the effect on libido?
Outside the trial record, the dose is described as shifting the effect on libido only loosely. A fall in desire appears at low doses and at high ones alike, though several accounts link the higher doses with stronger effects, and the exceptions run both ways: a fall within days where the dose was low, and thinner ejaculate with a heavier loss of desire where the dose sat well above those described elsewhere. In one isolated account outside the published trials, a very high dose is described as having raised testosterone, a change in the opposite direction.
The descriptions attributed to RAD140 doses are the hardest of all to read, since most of the accounts behind them involved other compounds as well. Suppression of the body’s own testosterone is generally held to deepen as the dose rises, and effects on desire are described as stronger at the higher end. The relation is not strict, however, since marked suppression is also described at low doses.
Hormone recovery in the case report after the supplements stopped
Once the supplements were discontinued the patient’s symptoms resolved fully: the bilateral gynaecomastia settled and the hypogonadotropic hypogonadism normalised, with the measured values back inside their reference ranges. A suppression that reversed once the supplements stopped is the strongest statement this evidence supports in humans, and it rests on a single patient whose products also held undeclared hormones. The published record gives no interval to normalisation, so no recovery window can be read from the case.
The case patient before and after stopping
How long does low libido last after a RAD140 cycle and PCT?
Low libido after exposure to RAD140 ends is generally held to last from a few weeks to several months, lifting as the hypothalamic-pituitary-gonadal axis recovers. The axis is held to recover more slowly after longer or heavier exposure, and the medicines given once exposure ends have not been shown to guarantee a faster return.
Outside the published trials, low libido is described as running much the same course: desire returned within weeks in some accounts and stayed low for many months in others, and in a few it fell only after exposure had ended. Beyond the trial data, some of those courses are described as followed by medicines meant to restart endogenous hormone production, which the accounts call post-cycle therapy, or RAD 140 PCT.
In those accounts, where desire stays low for months, the usual next step in the medical literature is RAD 140 blood work: serum testosterone, luteinising hormone, follicle-stimulating hormone, oestradiol and prolactin, a pituitary hormone whose excess dampens sexual desire. Those measurements let persistent secondary hypogonadism, or another cause, be sought rather than assumed.
Does libido always come back after stopping, or can the loss be lasting?
In descriptions beyond the trials, libido returns in most cases once exposure ends, though in a few the recovery is described as incomplete and the loss as possibly permanent. Incomplete recovery of erectile function has also been described as a rare outcome, usually where several compounds were present at once, while desire has elsewhere been described as returning more strongly than before.
In those accounts a return of libido is the usual outcome, because desire tracks the testosterone produced by the testes and that production is widely understood to recover over the following months. Delayed or incomplete recovery is recognised after high-dose or prolonged exposure and after combinations of several androgenic compounds.
Does PCT actually bring libido and erections back?
Outside the trials, PCT brings desire and erections back in some accounts and fails to bring them back in others. The medicines in those accounts include enclomiphene, a selective oestrogen receptor modulator (SERM) that raises luteinising hormone, and human chorionic gonadotrophin (hCG), a hormone that stimulates the testes directly. The outcomes described after PCT are these:
In those accounts SERMs raise luteinising hormone and testosterone where testicular production has been suppressed, and sexual function follows that recovery, though the timing of the recovery varies.
What RAD140 supplements were found to contain
All three supplements in the case report turned out to hold testosterone, oestradiol and growth hormone, none of them named on the labels, and by liquid chromatography mass spectrometry, which separates compounds and identifies them by mass, it found an unidentified compound co-eluting close to the testosterone peak. The Australian medicines regulator, the Therapeutic Goods Administration (TGA), found the opposite fault in its own testing: unapproved SARM products were significantly under-dosed, that is, they supplied less of the declared compound than the label stated. Undeclared hormones on one side and under-dosing on the other bracket the problem of RAD140 quality.
For libido that means an effect described outside the trials may come from a hormone that nobody declared, or may not come from RAD140 at all where too little of the compound was present to act.
Laboratory work is in a different position, because the contents of a vial can be known before an experiment begins. The RAD-140 for sale in our shop comes with batch and purity data for each lot, and the same documentation covers the rest of our UK SARMs range.
What the animal studies show about RAD140 and the brain
The animal studies on RAD140 and the brain show that the compound reaches the brain and produces androgen action there. RAD140 matched testosterone in reducing cell death from apoptotic insults in cultured rat hippocampal neurons, and the authors traced that neuroprotection to MAPK signalling through the mitogen-activated protein kinase cascade, because an inhibitor of that cascade abolished it.
The whole-animal work used adult male rats that had been gonadectomised, surgically deprived of their gonads. In them the SARM RAD140 produced androgen action in peripheral tissues while largely sparing the prostate, switched on androgenic gene regulation in the brain and reduced the loss of hippocampal neurons after an excitotoxic kainate lesion. An earlier characterisation across rat and monkey models had already described the compound as potent and orally bioavailable.
These data supply the biological ground that any claim about desire would need, since such a claim begins with androgen action in the brain. They measured neuronal survival, gene regulation and the response of peripheral tissues, not sexual behaviour or erectile function.
RAD140 in the animal studies
Limits of the evidence on RAD140 and sex drive
The human evidence assembled here amounts to one case report, whose products held hormones their labels did not name and whose record describes hormonal and breast-tissue findings rather than libido. The animal studies measured neuronal and peripheral-tissue outcomes, so they cannot be read as data on sexual function. Everything else comes from descriptions outside the trials, which measurement does not confirm and which often involve several compounds at once and products of unknown content. Those limits cut both ways: such material can neither confirm nor rule out a rise in desire or its loss. No trial among this article’s sources measured libido, erectile function or recovery under the compound.
What each source measured on RAD140
Frequently asked questions
Can RAD140 cause erectile dysfunction?
Outside the published trials RAD140 is linked with reduced rigidity, the absence of any erection and lost morning erections, and in other accounts with greater rigidity than usual. The mechanism generally held to apply is indirect, through suppression of endogenous testosterone rather than any direct action on penile tissue, and no controlled study has measured erectile function under the compound.
How long does low libido last after a cycle?
From a few weeks to several months, as a rule. Outside the published trials the course is described the same way, desire returning within weeks in some accounts and staying low months later in others, and where it persists, hormonal blood testing is the usual next step in clinical practice.
In which week does the libido drop usually start?
Outside the trial record, the fall is placed a few weeks into exposure, after a rise in the first days or weeks. A minority of accounts put it within the first days, others only after exposure had ended, so no single week is typical.
On the question of whether RAD 140 increases libido, the early rise in sex drive and its later fall, erectile dysfunction, the loss of morning erections and low libido lasting after exposure has ended are known only from descriptions outside the trials. No published study among this article’s sources has measured them.
Check what you remember
4 questions on this article; the right answer is marked.
Besides RAD-140, MK-677 and cardarine, all three products held testosterone, oestradiol and growth hormone that no label named, so the man's suppression cannot be pinned on RAD140 alone.
Stopping the supplements led to full resolution of his symptoms, including normal reproductive hormones, though the report recorded neither libido nor erections and gave no time to recovery.
RAD140 activated androgenic gene regulation in the rat brain and reduced neuron loss after kainate while largely sparing prostate, but sexual behaviour was never measured.
The TGA found unapproved SARM products contained significantly less of the declared compound than their labels claimed, so a described effect may not come from RAD140 at all.
Elizabeth Hyams · Imperial College London
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Bonnie Grant, MBBS · Imperial College London · Last reviewed
Postdoctoral Clinical Research Fellow; Specialty Registrar in Endocrinology and Diabetes
Bonnie Grant is a postdoctoral clinical research fellow and a specialty registrar in endocrinology and diabetes in the Department of Metabolism, Digestion and Reproduction at Imperial College London. Bonnie specialises in reproductive medicine and fertility.
Related Posts
How bad is RAD-140 for the heart? What the evidence shows
How bad is RAD-140 for the heart remains unmeasured in published studies, while case reports describe myocarditis and heart failure after exposure.
Is RAD-140 bad for kidneys? What the case reports show
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.
RAD 140 lethargy: mood, sleep and what the evidence shows
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
RAD 140 side effects: what the trials and case reports show
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.